BIA 10-2474 (original) (raw)
BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. It interacts with the human endocannabinoid system. The drug was in development for the treatment of a range of different medical conditions from anxiety disorder to Parkinson's disease, also for the treatment of chronic pain of multiple sclerosis, cancer, hypertension or the treatment of obesity. A clinical trial with this drug was underway in Rennes, France, in January 2016, in which serious adverse events occurred affecting five participants, including the death of one man. The underlying mechanism that caused the acute neurotoxicity of this molecule remains unknown.
| Property | Value |
|---|---|
| dbo:abstract | BIA 10-2474 ist ein experimenteller Inhibitor der Fettsäureamid-Hydrolase, der von dem portugiesischen Pharmaunternehmen Bial Portela e C.ª, S.A. entwickelt wurde. Er interagiert mit dem menschlichen Endocannabinoid-System. Der Wirkstoff wurde entwickelt, um Schmerz zu lindern, zur Stimmungsaufhellung, um Angstzustände zu behandeln und um die Bewegungskoordination bei neurodegenerativen Erkrankungen zu verbessern. Bei einer klinischen Studie mit dem Wirkstoff kam es am 15. Januar 2016 in Rennes (Frankreich) zu schweren neurologischen Nebenwirkungen mit einem Todesfall. Laut der französischen Tageszeitung Le Figaro handelt es sich bei BIA 10-2474 um 3-(1-(Cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridin-1-oxid. (de) BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. It interacts with the human endocannabinoid system. The drug was in development for the treatment of a range of different medical conditions from anxiety disorder to Parkinson's disease, also for the treatment of chronic pain of multiple sclerosis, cancer, hypertension or the treatment of obesity. A clinical trial with this drug was underway in Rennes, France, in January 2016, in which serious adverse events occurred affecting five participants, including the death of one man. The underlying mechanism that caused the acute neurotoxicity of this molecule remains unknown. (en) Le BIA 10-2474 est un inhibiteur expérimental du système enzymatique FAAH en phase d'essai jusqu'en janvier 2016 par le laboratoire Bial, leader de l'industrie pharmaceutique portugaise. La molécule, testée comme antalgique, entre en interaction, au sein de l'organisme humain, avec le système endocannabinoïde. À la suite d'un essai clinique mortel chez son prestataire Biotrial, Bial abandonne définitivement ses recherches sur cette molécule. (fr) BIA 10-2474 — экспериментальный ингибитор , разрабатываемый португальской фармацевтической компанией Bial-Portela & Ca. SA. Лекарственный препарат разрабатывается для лечения боли, коррекции настроения и тревожных расстройств, а также двигательных нарушений при нейродегенеративных заболеваниях. Влияет на человека. В январе 2016 г. применение препарата в рамках клинического исследования, проводимого в г. Ренн, Франция, привело к развитию у 5 пациентов и, по меньшей мере, одному летальному исходу. (ru) |
| dbo:casNumber | 1233855-46-3 |
| dbo:fdaUniiCode | 5AP1ZW859M |
| dbo:pubchem | 46831476 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Bia102474_corrected.svg?width=300 |
| dbo:wikiPageExternalLink | http://cdsouthan.blogspot.com.au/2016/01/molecular-details-related-to-bia-10-2474.html http://www.biotrial.com/ http://www.cyclicarx.com/bia-10-2474/ http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/special_topics/general/general_content_000489.jsp https://www.bial.com/en/r_d.2/pipeline.29/pipeline.a27.html http://webarchive.nationalarchives.gov.uk/20130224001257/http:/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063117%7C http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063117%7C https://pubchem.ncbi.nlm.nih.gov/compound/46831476 https://web.archive.org/web/20160126095352/http:/www.chu-rennes.fr/sections http://www.bmj.com/content/352/bmj.i466 |
| dbo:wikiPageID | 49110893 (xsd:integer) |
| dbo:wikiPageLength | 80922 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1119900878 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Cancer dbr:Royal_Statistical_Society dbr:Sanofi dbr:Sarthe dbr:Enzyme_inhibitor dbr:Nervous_system dbr:MST1R dbr:Brain_dead dbr:Departments_of_France dbr:Designer_drug dbr:Anti-inflammatory dbr:Anxiety_disorder dbr:Hypertension dbr:Johnson_&_Johnson dbr:Bial dbr:Pfizer dbr:Pharmacology dbr:Rennes dbr:Rennes_University_Hospital dbr:Risk_assessment dbr:Inflammation dbr:Investigator's_brochure dbr:Neurotransmitter dbc:Cyclohexyl_compounds dbc:Imidazoles dbc:Ureas dbr:Corticosteroid dbr:Maximum_tolerated_dose dbr:Gendarmerie dbr:Nature_(journal) dbr:Nausea dbr:No-observed-adverse-effect_level dbr:Endocannabinoid_system dbr:Enzyme dbr:Brain dbr:Ministry_of_Justice_(France) dbr:Monoclonal_antibody dbr:Morbihan dbr:Multiple_sclerosis dbr:Blind_experiment dbr:Contract_research_organization dbr:Crossover_study dbr:Open-label_trial dbr:Arachidonoyl_serotonin dbr:Lesions dbr:Liver dbr:Loi_Huriet_Sérusclat dbr:MK-4409 dbr:Stroke dbr:Clinical_trial dbr:Fatty_acid_amide_hydrolase dbr:Federal_Institute_for_Drugs_and_Medical_Devices dbr:Clearance_(medicine) dbr:Hormone-sensitive_lipase dbr:Pain dbr:Patent dbr:Pharmacodynamics dbr:Pons dbr:Symptom dbr:Brittany_(administrative_region) dbr:Toxicology dbr:Drug_class dbr:Drug_discovery dbr:Leaving_group dbr:Agence_Nationale_de_Sécurité_du_Médicament_et_des_Produits_de_Santé dbr:Alcoholism dbr:Analgesic dbr:Anandamide dbr:4-Nonylphenylboronic_acid dbc:Amine_oxides dbr:European_Investment_Bank dbr:European_Medicines_Agency dbr:Faeces dbr:Fialuridine dbr:Food_and_Drug_Administration dbr:PF-04457845 dbr:Parkinson's_disease dbr:Carboxylesterase dbr:Central_nervous_system dbr:Chronic_pain dbr:Hippocampus dbr:Judiciary dbr:Disorder_(medicine) dbr:Priority_right dbr:Protocol_(science) dbr:Radioactivity dbr:Histone_deacetylase dbr:Adaptive_clinical_trial dbr:JNJ-42165279 dbr:First-in-man_study dbc:Serine_protease_inhibitors dbr:LY-2183240 dbr:La_Flèche dbr:Le_Figaro dbr:Bioavailability dbr:Biological_half-life dbr:Blood dbr:Eating dbr:High-throughput_screening dbr:Patent_family dbc:Clinical_trial_disasters dbr:Marisol_Touraine dbr:Human_equivalent dbr:Merck_&_Co. dbr:Metabolism dbr:Metabolites dbr:Necrosis dbr:Obesity dbr:Random_assignment dbr:Mechanism_of_action dbr:Serious_adverse_event dbr:Sleep dbr:Urine dbr:Vernalis_plc dbr:Neurology dbr:IC50 dbr:Pharmacokinetics dbr:Safety_pharmacology dbr:Spinal_cord dbr:Monoacylglycerol_lipase dbr:Toxicology_testing dbr:Janssen-Cilag dbr:The_New_England_Journal_of_Medicine dbr:TGN1412 dbr:Haemorrhagic dbr:URB-597 dbr:Radio_labelling dbr:Target_affinity dbr:Inhibition_constant dbr:Brain_MRI dbr:Medical_conditions dbr:The_British_Medical_Journal |
| dbp:c | 16 (xsd:integer) |
| dbp:casNumber | 1233855 (xsd:integer) |
| dbp:chemspiderid | 41628677 (xsd:integer) |
| dbp:h | 20 (xsd:integer) |
| dbp:iupacName | 3 (xsd:integer) |
| dbp:iupharLigand | 9001 (xsd:integer) |
| dbp:legalUs | Investigational New Drug (en) |
| dbp:n | 4 (xsd:integer) |
| dbp:o | 2 (xsd:integer) |
| dbp:pubchem | 46831476 (xsd:integer) |
| dbp:routesOfAdministration | Oral (en) |
| dbp:smiles | CNC1CCCCC1 (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | DOWVMJFBDGWVML-UHFFFAOYSA-N (en) |
| dbp:unii | 5 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:More_science_citations_needed dbt:Better_source_needed dbt:Cannabinoidergics dbt:Cannabinoids dbt:Cite_journal dbt:Cite_web dbt:Clear dbt:Columns-list dbt:Drugbox dbt:Primary_source_inline dbt:Reflist dbt:Short_description dbt:Update_inline dbt:Fdacite |
| dcterms:subject | dbc:Cyclohexyl_compounds dbc:Imidazoles dbc:Ureas dbc:Amine_oxides dbc:Serine_protease_inhibitors dbc:Clinical_trial_disasters |
| gold:hypernym | dbr:Inhibitor |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. It interacts with the human endocannabinoid system. The drug was in development for the treatment of a range of different medical conditions from anxiety disorder to Parkinson's disease, also for the treatment of chronic pain of multiple sclerosis, cancer, hypertension or the treatment of obesity. A clinical trial with this drug was underway in Rennes, France, in January 2016, in which serious adverse events occurred affecting five participants, including the death of one man. The underlying mechanism that caused the acute neurotoxicity of this molecule remains unknown. (en) Le BIA 10-2474 est un inhibiteur expérimental du système enzymatique FAAH en phase d'essai jusqu'en janvier 2016 par le laboratoire Bial, leader de l'industrie pharmaceutique portugaise. La molécule, testée comme antalgique, entre en interaction, au sein de l'organisme humain, avec le système endocannabinoïde. À la suite d'un essai clinique mortel chez son prestataire Biotrial, Bial abandonne définitivement ses recherches sur cette molécule. (fr) BIA 10-2474 — экспериментальный ингибитор , разрабатываемый португальской фармацевтической компанией Bial-Portela & Ca. SA. Лекарственный препарат разрабатывается для лечения боли, коррекции настроения и тревожных расстройств, а также двигательных нарушений при нейродегенеративных заболеваниях. Влияет на человека. В январе 2016 г. применение препарата в рамках клинического исследования, проводимого в г. Ренн, Франция, привело к развитию у 5 пациентов и, по меньшей мере, одному летальному исходу. (ru) BIA 10-2474 ist ein experimenteller Inhibitor der Fettsäureamid-Hydrolase, der von dem portugiesischen Pharmaunternehmen Bial Portela e C.ª, S.A. entwickelt wurde. Er interagiert mit dem menschlichen Endocannabinoid-System. Der Wirkstoff wurde entwickelt, um Schmerz zu lindern, zur Stimmungsaufhellung, um Angstzustände zu behandeln und um die Bewegungskoordination bei neurodegenerativen Erkrankungen zu verbessern. Bei einer klinischen Studie mit dem Wirkstoff kam es am 15. Januar 2016 in Rennes (Frankreich) zu schweren neurologischen Nebenwirkungen mit einem Todesfall. (de) |
| rdfs:label | BIA 10-2474 (de) BIA 10-2474 (en) BIA 10-2474 (fr) BIA 10-2474 (ru) |
| owl:sameAs | yago-res:BIA 10-2474 wikidata:BIA 10-2474 dbpedia-de:BIA 10-2474 dbpedia-fr:BIA 10-2474 dbpedia-ru:BIA 10-2474 https://global.dbpedia.org/id/25nMr |
| prov:wasDerivedFrom | wikipedia-en:BIA_10-2474?oldid=1119900878&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Bia102474_corrected.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:BIA_10-2474 |
| is dbo:wikiPageRedirects of | dbr:BIA_102474 dbr:2016_French_drug_trial_death dbr:2016_French_drug_trial_disaster dbr:Rennes_clinical_trial dbr:Rennes_drug_trial |
| is dbo:wikiPageWikiLink of | dbr:Bial dbr:Death_of_Dan_Markingson dbr:MK-4409 dbr:Fatty_acid_amide_hydrolase dbr:Post-traumatic_stress_disorder dbr:PF-04457845 dbr:JNJ-42165279 dbr:LY-2183240 dbr:C16H20N4O2 dbr:Serious_adverse_event dbr:Theralizumab dbr:BIA_102474 dbr:2016_French_drug_trial_death dbr:2016_French_drug_trial_disaster dbr:Rennes_clinical_trial dbr:Rennes_drug_trial |
| is foaf:primaryTopic of | wikipedia-en:BIA_10-2474 |
